GlaxoSmithKline and Sirtris Pharmaceuticals Incorporated announced on April 22 that they have entered into a definitive agreement pursuant to which GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million (or approx. GBP362 million) through a cash tender offer of USD22.50 (or approx. GBP11.33) per share.
GlaxoSmithKline to acquire Sirtris Pharmaceuticals